Antonios Christou
Expertise in
20
conditions

Dr. Antonios Christou

Oncology | Hematology
1301 Carlisle Street, 
Natrona Heights, PA 
Accepting New Patients
Expertise in
20
conditions
1301 Carlisle Street, 
Natrona Heights, PA 

Overview

Antonios Christou is an Oncologist and a Hematologist practicing medicine in Natrona Heights, Pennsylvania.

Dr. Christou is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Angiosarcoma, Lung Cancer, Inflammatory Breast Cancer, and Small Cell Lung Cancer (SCLC).

Dr. Christou is board certified in Medical Oncology, American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 7 clinical trials. Dr. Christou is currently accepting new patients.

Specialties

Oncology
Hematology

Licenses

Internal Medicine in PA

Board Certifications

Medical Oncology, American Board Of Internal Medicine

Fellowships

Indiana University Medical Center

Hospital Affiliations

Forbes Hospital
Allegheny Valley Hospital
Acmh Hospital
Allegheny General Hospital
West Penn Hospital

Languages Spoken

English
French
Greek

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

AHN Cancer Institute-Med Onc & Infusions at Allegheny Valley Hospital
1301 Carlisle Street, Natrona Heights, PA 15065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor
Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2026
Intervention Type: Drug
Study Drugs: Palbociclib, Fulvestrant
Study Phase: Phase 2
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

4 Total Publications

Clinical presentation, MRI and clinical outcome scores do not accurately predict an important meniscal tear in a symptomatic discoid meniscus.
Clinical presentation, MRI and clinical outcome scores do not accurately predict an important meniscal tear in a symptomatic discoid meniscus.
Journal: Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA
Published: June 02, 2020
Similar Doctors
Expertise in
11
conditions
Dr. Diwakar Davar
Hematology | Oncology
Expertise in
11
conditions
Dr. Diwakar Davar
Hematology | Oncology
Referral may be required
Before you request

Upmc Division Of Surgical Oncology

5115 Centre Ave, Ste 2, 
Pittsburgh, PA 
 (15.6 miles away)
Languages Spoken:
English, Tamil
See accepted insurances
Accepting New Patients
Offers Telehealth

Diwakar Davar, MBBS, M.Sc is an assistant professor of medicine and a medical oncologist/hematologist. He specializes in the management of advanced melanoma and the development of early phase studies to test novel immunotherapeutic approaches to treat advanced cancers.;. Dr. Davar is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Metastatic Uveal Melanoma, Uveal Melanoma, and Gamma Knife Radiosurgery. Dr. Davar is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Davar is currently accepting new patients.

Expertise in
4
conditions
Dr. Kelly M. Bailey
Hematology | Oncology
Expertise in
4
conditions
Dr. Kelly M. Bailey
Hematology | Oncology
Referral may be required

UPMC Children's Hospital Of Pittsburgh

4401 Penn Ave, 
Pittsburgh, PA 
 (15.5 miles away)
412-692-6644
Languages Spoken:
English
See accepted insurances

Kelly Bailey is a Hematologist and an Oncologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Bailey is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, and Bone Tumor.

Expertise in
47
conditions
Dr. David M. Friedland
Hematology | Oncology
Expertise in
47
conditions
Dr. David M. Friedland
Hematology | Oncology
Referral may be required

Office

2 Hot Metal St, 
Pittsburgh, PA 
 (17.9 miles away)
412-235-1020
Languages Spoken:
English
See accepted insurances

David Friedland is a Hematologist and an Oncologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Friedland is highly rated in 47 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Antonios Christou

How do I make an appointment with Dr. Antonios Christou?

You can book an appointment with Dr. Antonios Christou by calling their office at 724-226-7105. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Antonios Christou a top-rated expert for Angiosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Antonios Christou is classified as an Distinguished expert for Angiosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Antonios Christou specialize in?

While Dr. Antonios Christou is a Oncology, they have specific expertise in Angiosarcoma, Lung Cancer, and Inflammatory Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Antonios Christou participate in research or clinical trials?

Yes. Dr. Antonios Christou has published 4 articles and abstracts on conditions like Angiosarcoma. You can view a list of Dr. Antonios Christou's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Antonios Christou accept my insurance?

Dr. Antonios Christou accepts most major insurance plans, including Aetna and CareSource. We recommend calling the office directly at 724-226-7105 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Christou's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 72 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile